Cartesian Therapeutics, Inc.
RNAC
Rank in Stocks
#18551
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Share Price
$6.08
Market Cap
$183.95M
Change (1 day)
-3.03%
Change (1 year)
811.13%
Country
US
Trade Cartesian Therapeutics, Inc. (RNAC)
Category
Healthcare
P/S ratio for Cartesian Therapeutics, Inc. (RNAC)
P/S ratio as of 2026 TTM: 0
According to Cartesian Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Cartesian Therapeutics, Inc. from 2026 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
